The linearly decreasing convergence factor a. حسب Junhao Wei (6816803)

Overview of the six original ACTIV-3/TICO trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Baseline patient characteristics. حسب Oscar F. C. van den Bosch (22184246)

الموضوعات:

Effects of s-ketamine and midazolam on respiratory parameters. حسب Oscar F. C. van den Bosch (22184246)

الموضوعات:

Flow chart of the study participants. حسب Oscar F. C. van den Bosch (22184246)

الموضوعات:

Results of dose linearity. حسب Masakazu Tsujimoto (22339504)

S2 File - Factors influencing effective decrease of controlled attenuation parameters in metabolic-associated steatotic liver disease: A multilevel linear regression analysis at Vajira Hospital حسب Sonsawan Sangprasert (22772538)

"…S2 File - <p>Factors influencing effective decrease of controlled attenuation parameters in metabolic-associated steatotic liver disease: A multilevel linear regression analysis at Vajira Hospital</p>…"

ANN architecture. حسب Abdelfattah Dani (22226715)

الموضوعات:

Association of each health behavior and the reported decrease in psychological well-being during the pandemic between individuals who often/very often compared to rarely/never engaged in health behaviors. Results are predicted means and 95% confidence intervals from linear model analysis adjusted for age, gender, worked in patient care, had school aged children, near high-risk relatives and in high-risk group.... حسب Elie Mulhem (22537863)

الموضوعات:

Effect of each health behavior on the reported decrease in physical health during the pandemic between individuals who often/very often compared to rarely/never engaged in health behaviors. Results are predicted means and 95% confidence intervals from linear model analysis adjusted for age, gender, worked in patient care, had school aged children, near high-risk relatives and in high-risk group.... حسب Elie Mulhem (22537863)

الموضوعات:

Estimated mean values for light interception. حسب Torsten Schober (20485754)

الموضوعات:

ANN architecture and configuration. حسب Abdelfattah Dani (22226715)

الموضوعات:

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات: